- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02800109
Child Follow-up Until 2 Years
Impact of Malaria Infection in Pregnancy on Fetal and Newborn Growth - Child Follow-up Until 2 Years of Age, in Relation to the Fetal Growth
The purpose of this study is to measure the impact of maternal malaria on child growth in the two first years of life in relation to fetal growth.
This study is following a birth cohort of children born to pregnant women enrolled in the study "Impact of malaria infection in pregnancy on fetal and newborn growth" (protocol OXTREC 14 08 and Mahidol 2009-003-01). In this cohort growth monitoring is conducted until 2 years of age using routine anthropometric measurements such as weight, length, arm and head circumference. A few additional tests will enhance the sensitivity of the study outcomes with minimal risk. These tests will include anthropometry, screening, nutrition questionnaire and neurodevelopmental assessment.
This study was funded by Wellcome Trust core funding, grant ref. number Wellcome Trust Major Overseas Program Grant no. 220211 (2020-2025)
Study Overview
Detailed Description
This is an existing on-going prospective birth cohort of children born to the pregnant women who had fetal growth assessed during pregnancy. In this cohort an expected 10% of pregnant women will be exposed to malaria while the remaining will be free of malaria. Their offspring are already followed up for growth monitoring from birth until 2 years of age with anthropometric measurements including weight, length, arm and head circumference at each scheduled visit. The investigator would like to enhance the sensitivity of the study outcomes with minimal risk for the child by proposing the following anthropometric and screening tests, nutrition questionnaire, and neurodevelopment assessment. In addition a prospective cohort of children born after study approval will be followed on both protocols. The additional measure include:
- Body fat composition (at birth, and monthly up to 4 months unless weight ≥ 8kg)
- Triceps and subscapular skinfold (at 1 and 2 years)
- Anemia, malaria and soil-transmitted helminths screening (every 3 months in first 12 months and 6-monthly 1-2 years)
- Buccal swab (at 1 and 2 years)
- Neurodevelopment (every 6 months)
- Food questionnaire (at 1 and 2 years)
Summary of results:
The beginning of the recruitment was delayed until the finalization and approval of the translated PIS/ICF; from then on, the recruitment was smooth. Overall, 201 children from the ongoing existing birth cohort were still present and eligible to participate in this part of the study; 173 completed 2 years of FUP 28 were lost. Data and samples from these 173 children were included in the analysis of a large, multi-center, study, the INTERBIO-21st.
The pooled findings show 1. Cognitive development, language, and visual skills at 2 years of age vary according to the trajectories of fetal cranial growth 2. There is a critical window period at 20-25 weeks gestational age when fetal cranial trajectories may diverge and when fetal abdominal circumference growth may accelerate or decelerate 3. Preterm newborn's growth and neurocognitive development vary according to their birth phenotype characteristics (i.e. those classified in the "birth infections" phenotype were at higher risk for poor scoring in fine and gross motor development compared to term newborns) 4. An indication of a greater increase in weight in proportion to height during the 2 first years of life if there was a faltering growth phenotype observed during gestation.
Maternal malaria and anemia's role in the development of children were evaluated specifically for this study site and included all the children followed up to one year of age. Preliminary results show that 48% of children are stunted at 2 years of age and that malaria and anemia independently are significant contributors to the decline in growth z-scores during infancy (manuscript in preparation); that 66% of children have anemia (HCT<33%) in the first year of life, the median age for a first HCT<33% is 4 months of age and that moderate, but not mild anemia in infancy reduces the median neurodevelopment score at year of age. Maternal anemia but not malaria is a factor contributing to increased risk of anemia in infants. Results were presented at local and regional and international conferences and were part of a MSc thesis.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Tak
-
Mae Sot, Tak, Thailand, 63110
- Shoklo Malaria Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant's parent or legal guardian is willing and able to give informed consent for participation in the study
- Able (in the Investigators opinion) to comply with study requirements
Exclusion Criteria:
The participant may not enter the study if ANY of the following apply:
- Medical or congenital complications which would (in the investigator's opinion) make it difficult to comply with study requirements
- Aged older than 2 years
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of children with sub-optimal growth by 2 years of age among children born to mother exposed to malaria and those born to mother non-exposed to malaria
Time Frame: up to 2 years of age
|
up to 2 years of age
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The median neurocognitive scores by growth groups and malaria-exposed groups
Time Frame: up to 2 years of age
|
up to 2 years of age
|
The median age of onset of anemia by growth groups and malaria-exposed Groups
Time Frame: up to 2 years of age
|
up to 2 years of age
|
Characterize of molecular signatures (methylation profile of the DNA) by growth groups and malaria-exposed groups
Time Frame: up to 2 years of age
|
up to 2 years of age
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMRU1504
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Turku University HospitalUniversity of TurkuCompleted
-
Centre Hospitalier René DubosCompletedDeciduitis; Complicating Pregnancy